Organic compounds -- part of the class 532-570 series – Organic compounds – Azo
Reexamination Certificate
2004-07-28
2009-02-03
Powers, Fiona T (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Azo
C540S456000, C546S197000
Reexamination Certificate
active
07485706
ABSTRACT:
Methods and compositions are provided for reducing aggregation of neurodegenerative proteins associated with neurotoxicity or other proteins. The compounds comprise a first domain or targeting element for binding to the target proteins linked to a second domain or recruiting element that binds to an aggregation inhibiting protein, e.g. a prolyl isomerase. By associating the aggregating forming proteins or neuronal cells under conditions where aggregating proteins are produced with the compound and the aggregation inhibiting protein, aggregation is reduced. The subject agents can be used in assays, investigating the etiology of the neuronal diseases and for prophylaxis and therapy.
REFERENCES:
patent: 5177203 (1993-01-01), Failli et al.
patent: 5346893 (1994-09-01), Failli et al.
patent: 5830462 (1998-11-01), Crabtree et al.
patent: 6011018 (2000-01-01), Crabtree et al.
patent: 6150527 (2000-11-01), Holt et al.
patent: 6316418 (2001-11-01), Crabtree et al.
patent: 6372712 (2002-04-01), Briesewitz et al.
patent: 2003/0130484 (2003-07-01), Gordon et al.
patent: 2007/0054348 (2007-03-01), Gestwicki et al.
patent: 2008/0085238 (2008-04-01), Li et al.
patent: 778023 (1997-06-01), None
Gestwicki et al., Science, 306(5697), 865-869, Jun. 2004.
Frid et al., Brain Research Reviews, 53(1), 135-160, Jan. 2007.
Ishii et al., Neuroscience Letters, 333, 5-8, 2002.
Lorenzo et al., Proc. Natl. Acad. Sci., 91, 12243-12247, Dec. 1994.
Gestwicki et al., Bifunctional small molecules as inhibitors of amyloidogenic protein-protein interactions. In: Abstracts of papers, 227thACS National Meeting, Anaheim CA, Mar. 28-Apr. 1, 2004, MEDI-188, Washington DC: American Chemical Society.
Iida et al. FK506-binding protein-type peptidyl-prolyl cis-trans isomerase from a halophilic archaeum, Halobacterium cutirubrum, Gene. 2000, vol. 256, pp. 319-326.
Briesewitz, et al., “Affinity modulation of small-molecule ligands by borrowing endogenous protein surface”, 1999 PNAS USA 96, 1953-8.
Cairo, et al., “Affinity-based inhibition of β-amyloid toxicity”, 2002 Biochemistry 41, 8620-9.
Ghanta, et al., “A strategy for Designing Inhibitors of β-amyloid toxicity”, 1996 J Biol Chem 271, 29525-28.
Goedert “Alpha-synuclein and Neurodegenerative Diseases”, 2001 Nature Reviews/Neuroscience 2, 482-501 (.alpha-synuclein).
Goedert “Pinning down phosphorylated tau”, Nature, 1999, vol. 399, p. 739.
Gordan, D. J. and Meredith, S. C. “Probing the role of backbone hydrogen bonding in β-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions”, (2003) Biochemistry 42:475-485.
Graef, I. A. et al., L-type calcium channel and GRK-3 regulate the activity of NF-Atc4 in hippocampal neuronns, 1999 Nature 401: 1703-1708.
Gordan, D. J. and Meredith, S. C. “Probing the role of backbone hydrogen Bonding in β-amyloid Fibrils with inhibitor peptides containing ester bonds at alternate positions”, (2003) Biochemistry 42:475-485.
Hardy and Selkoe “The amyloid hypoythesis of alzheimer's disease: process and problems on the road to therapeutics”, 2002 Science 297, 353-6.
Hammarstrom, P. et al., “Prevention of transthyretin amyloid disesae by changing protein misfolding energetics”, (2003) Science 299:713-716.
Korth, et al., “Acridine and phenothiazine derivatives as phatmacotherapeutics for prion disease”, 2001 PNAS 98, 9836-41.
Kim and Lee, “Fullerence Inhibits β-amyloid peptide aggregation”, 2003, Biochem Biophys Res Comm 303, 576-9.
Koo, E. H. et al., “Amyloid diseases: abnormal protein aggregation in neurodegeneration”, (1999) Proc. Natl. Acad. Sci. USA 96:9989.
Kayed, R. et al “Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis”, (2003) Science 300:486.
Kim, Y-S. et al “Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation”, (2003) J. Biol. Chem. 278:10842-10850.
Klettner and Henlegen “FK506 and its analogs- therapeutic potential for neurological disorders”, (2003) Curr Drug Target CNS Neurol Disord 2, 152-62-FK506.
Klunk, W. E. et al “Chrysamine-G, a lipophilic analogue of congo red, inhibits Aβ-induced toxicity in PC12 cells”, (1998) Life Sciences 63:1807-1814.
Lowe, et al., Structure-function relationships for inhibitors of β-amyloid toxicity containing the recognition sequence KLVFF, 2001 Biochemistry 40, 7882-89.
Lee, 2002 Neurobiology of Aging 23, 1039-42.
Lu, et al., “The prolyl isomerase pin1 restores the function of alzheimer-associated phosphorylated tau protein” 1999 Nature 399, 784-788.
Lee, et al., Neurogenerative Tauopathies 2000 Ann Rev Neurosci 24, 1121-59.
Sacchettini, J. C. and Kelly, J. W. “Therapeutic stategies for human amyloid diseases”, (2002) Nature Rev. Drug Discovery 1:267-275.
Spencer, et al., “Controlling signal transduction with synthetic ligards”, 1983 Science 262, 1019-24.
Serpell, L. C. “Alzheimer's amyloid fibrils: structure and assembly”, (2000) Biochimica et Biophysica Acta 1502:16-30.
Volles, M. J. and Lansbury, P. T. Jr., “Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in parkinson's disease”, (2003) Biochemistry 42:7871-7878.
Zoghbi and Orr, “Glutamine repeats and neurodegeneration”, 2000 Ann Rev Neurosci 23, 217-47 (glutamine repeats).
Crabtree Gerald R.
Gestwicki Jason E.
Graef Isabella A.
Bozicevic Field & Francis LLP
Field Bret E.
Powers Fiona T
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Neurodegenerative protein aggregation inhibition methods and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neurodegenerative protein aggregation inhibition methods and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurodegenerative protein aggregation inhibition methods and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4054764